You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News and reporting on ovarian cancer.
The diagnostic will be covered when patients are tested according to the Japanese Organization of Hereditary Breast and Ovarian Cancer's criteria.
Following a positive interim analysis of the Phase III OVAL trial, Japan-based NanoCarrier plans to open trial sites for VBL Therapeutics' VB-111.
The large BRCA1 deletion, which was not captured by initial genetic testing, might be the reason for the patient's exceptional response to a PARP inhibitor.
Radboud University Medical Center researchers developed and validated the single-molecule molecular inversion probe-centered workflow for more efficient BRCA1/2 testing.
Researchers found tumor and microenvironment features of advanced ovarian cancers respond to combination PARP inhibitor and immune checkpoint treatment.
The intended use will be in newly diagnosed ovarian cancer patients who are responsive to platinum chemotherapy regardless of biomarker status.
The company filed the application based on the PAOLA-1 data, which showed HRD-positive ovarian cancer patients saw pronounced benefit from the combo.
The final national coverage decision stipulates that NGS germline tests for assessing hereditary breast and ovarian cancer risk must have FDA's blessing.
Myriad filed an sPMA for myChoice CDx despite GSK's confidence that Zejula will be approved in newly diagnosed ovarian cancer regardless of biomarker status.
Five Prime Therapeutics provided an update on the development of bemarituzumab and FPA150, and Gritstone Oncology discussed plans for its personalized immunotherapies.